Initiation of immune responses to SARS COV2 in the oral cavity and upper airway
Initiation of immune responses to SARS COV2 in the oral cavity and upper airway
批准号:
10990201
负责人:
GILL DIAMOND
金额:
$76.44万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-11-20 至 2027-03-31
中文摘要
摘要
感染严重急性呼吸综合征冠状病毒2(SARS-CoV-2)导致2019年冠状病毒疾病
(新冠肺炎),一种危及生命的疾病,多系统参与感染的一部分人。口头和
鼻咽(NP)上皮细胞表达SARS-CoV-2受体ACE2,感染
口腔/鼻咽腔可能是新冠肺炎发展的必经步骤。免疫反应
首先在ONP中产生的病毒对病毒的清除几乎肯定是至关重要的,但也可能在
在许多感染者中观察到高炎性损伤的发展。我们已经使用了单细胞(Sc)-
从不同种族的新冠肺炎患者预期队列中进行核糖核酸测序,以确定不同的亚群
NP内的纤毛上皮细胞是SARS-CoV-2感染的直接靶细胞,并已描述为先天
由直接感染和未感染的旁观者细胞内的这些细胞产生的抗病毒反应。
有趣的是,这项分析表明,死亡率的增加与迟钝的抗病毒基因反应有关
NP,这表明对鼻部病毒感染的成功先天反应是
成功的抗病毒反应。除了鼻子,有强有力的证据表明SARS-CoV-2可以感染
口腔上皮。虽然口腔内有几个解剖部位可能与抗病毒有关
反应,牙龈沟是一个独特的免疫活性位置,对维持口腔至关重要
健康。牙龈上皮既表达SARS-CoV-2受体ACE2,也表达宿主蛋白酶
TMPRSS2是病毒进入所必需的,但与鼻腔病毒相比显示出重要的免疫学差异
上皮细胞包括偏向IL-17相关的中性粒细胞反应。因此,我们的总体假设是
识别和增强成功的鼻腔和牙龈的先天和获得性细胞免疫反应
上皮细胞将为新冠肺炎带来新的治疗途径。要解决这一假设,请提出
以下目标:1.SARS-CoV-2后跨粘膜表面的细胞状态和病毒动力学分层
感染和疫苗接种;2.比较鼻和牙龈内的记忆T细胞反应
对SARS-CoV-2有成功的或致病的反应;以及3.表征宿主固有的调节
限制SARS-CoV-2感染在ONP内传播所必需的免疫防御机制
上皮细胞。为了实现这些目标,我们将分析来自COVID患者的人类ONP样本-
19,从新冠肺炎中恢复,并使用sc-rna-seq、流式细胞术等为新冠肺炎接种疫苗
分子生物学技术。完成后,该项目将定义保护性先天免疫和获得性免疫
SARS-CoV-2感染患者ONP的作用机制,提高了我们对
病毒诱导ONP中的免疫,并提供对这些途径如何影响疾病发病机制的洞察。
英文摘要
Abstract
Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019
(COVID-19), a life-threatening illness with multi-system involvement in a subset of infected individuals. Oral and
nasopharyngeal (NP) epithelial cells express the SARS-CoV-2 receptor ACE2, and infection of the
oral/nasopharyngeal cavity (ONP) is likely an obligate step in the development of COVID-19. Immune responses
first generated in the ONP are almost certainly crucial for viral clearance but may also play a central role in the
development of hyperinflammatory injury observed in many infected individuals. We have used single cell (sc)-
RNA sequencing from a racially diverse prospective cohort of COVID-19 patients to identify distinct subsets of
ciliated epithelial cells within the NP that are direct targets for SARS-CoV-2 infection and have described innate
anti-viral responses generated by those cells within both directly infected as well as non-infected bystander cells.
Interestingly this analysis demonstrates that increased mortality is linked to blunted anti-viral gene response in
the NP, suggesting that a successful innate response to viral infection in the nose is a critical component of a
successful anti-viral response. In addition to the nose, there is strong evidence that SARS-CoV-2 can infect the
oral epithelium. While there are several anatomic sites within the mouth that are likely involved in anti-viral
responses, the gingival sulcus is a unique immunologically active location that is crucial for maintaining oral
health. The gingival epithelium expresses both the SARS-CoV-2 receptor ACE2 as well as the host protease
TMPRSS2 necessary for viral entry, but exhibits important immunological differences compared to the nasal
epithelium including a bias towards IL-17 associated neutrophil responses. Thus, our overall hypothesis is that
identifying and enhancing successful innate and adaptive cellular immune responses of the nasal and gingival
epithelium will lead to novel therapeutic avenues for COVID-19. To address this hypothesis, propose the
following aims: 1. Stratify cell states and viral dynamics across mucosal surfaces following SARS-CoV-2
infection and vaccination; 2. Compare memory T cell responses within the nose and gingiva that are associated
with successful or pathogenic responses to SARS-CoV-2; and 3. Characterize the regulation of host innate
immune defense mechanisms that are essential to limit propagation of SARS-CoV-2 infection within ONP
epithelial cells. To accomplish these aims, we will analyze human ONP samples from individuals with COVID-
19, recovered from COVID-19, and vaccinated for COVID-19 using sc-RNA-seq, flow cytometry, and other
molecular biology techniques. At completion, the project will define the protective innate and adaptive immune
mechanisms operating in the ONP of patients infected with SARS-CoV-2, improve our overall understanding of
viral induced immunity in the ONP, and provide insight into how these pathways influence disease pathogenesis.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
Examination of gene expression in saliva samples from COVID-19 patients to study the host defense response against SARS-CoV-2 in the oral cavity.
检查来自Covid-19患者的唾液样本中的基因表达,以研究对口腔中SARS-COV-2的宿主防御反应。
DOI:
10.1111/omi.12327
发表时间:
2021-04
期刊:
Molecular oral microbiology
影响因子:
3.7
作者:
[Diamond G, Figgins EL, Robinson T, Senitko M, Abraham GE, Williams HB, Sloan M, Owings A, Laird H, Pride Y, Wilson KJ, Hasan M, Parker A, Glover SC]
通讯作者:
Glover SC
DOI:
10.3390/ijms24021654
发表时间:
2023-01-14
期刊:
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
影响因子:
5.6
作者:
[Darwish, Sara, Liu, Lauren P., Robinson, Tanya O., Tarugu, Spurthi, Owings, Anna H., Glover, Sarah C., Alli, Abdel A.]
通讯作者:
Alli, Abdel A.
Initiation of immune responses to SARS COV2 in the oral cavity and upper airway
-
批准号:10446223
-
项目类别:
-
资助金额:$82.2万
-
财政年份:2022
-
负责人:GILL DIAMOND
-
依托单位:
Initiation of immune responses to SARS COV2 in the oral cavity and upper airway
-
批准号:10579342
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2022
-
负责人:GILL DIAMOND
-
依托单位:
Antimicrobial peptide mimetic activity against Candida auris
-
批准号:10369013
-
项目类别:
-
资助金额:$23.04万
-
财政年份:2021
-
负责人:GILL DIAMOND
-
依托单位:
Topical Vitamin D and Periodontal Disease
-
批准号:10382267
-
项目类别:
-
资助金额:$54.2万
-
财政年份:2021
-
负责人:GILL DIAMOND
-
依托单位:
Topical Vitamin D and Periodontal Disease
-
批准号:10600091
-
项目类别:
-
资助金额:$46.23万
-
财政年份:2021
-
负责人:GILL DIAMOND
-
依托单位:
A Novel Therapeutic for Invasive Candidiasis
-
批准号:8871683
-
项目类别:
-
资助金额:$75.0万
-
财政年份:2014
-
负责人:GILL DIAMOND
-
依托单位:
2013 Antimicrobial Peptides GRC/GRS
-
批准号:8525670
-
项目类别:
-
资助金额:$0.5万
-
财政年份:2013
-
负责人:GILL DIAMOND
-
依托单位:
Vitamin D and Periodontal Disease
-
批准号:8733048
-
项目类别:
-
资助金额:$26.25万
-
财政年份:2012
-
负责人:GILL DIAMOND
-
依托单位:
Vitamin D and Periodontal Disease
-
批准号:8722700
-
项目类别:
-
资助金额:$9.46万
-
财政年份:2012
-
负责人:GILL DIAMOND
-
依托单位:
Vitamin D and Periodontal Disease
-
批准号:8767563
-
项目类别:
-
资助金额:$25.05万
-
财政年份:2012
-
负责人:GILL DIAMOND
-
依托单位:
Vitamin D and Periodontal Disease
-
批准号:8401686
-
项目类别:
-
资助金额:$18.36万
-
财政年份:2012
-
负责人:GILL DIAMOND
-
依托单位:
A Novel Antimicrobial Mimetic for Oral Candidiasis
-
批准号:8059854
-
项目类别:
-
资助金额:$48.55万
-
财政年份:2010
-
负责人:GILL DIAMOND
-
依托单位:
A Novel Antimicrobial Mimetic for Oral Candidiasis
-
批准号:8141211
-
项目类别:
-
资助金额:$49.05万
-
财政年份:2010
-
负责人:GILL DIAMOND
-
依托单位:
Vitamin D induction of antibacterial activity in gingival cells
-
批准号:7827661
-
项目类别:
-
资助金额:$1.66万
-
财政年份:2009
-
负责人:GILL DIAMOND
-
依托单位:
Vitamin D induction of antibacterial activity in gingival cells
-
批准号:7694341
-
项目类别:
-
资助金额:$23.4万
-
财政年份:2008
-
负责人:GILL DIAMOND
-
依托单位:
Vitamin D induction of antibacterial activity in gingival cells
-
批准号:7588270
-
项目类别:
-
资助金额:$19.5万
-
财政年份:2008
-
负责人:GILL DIAMOND
-
依托单位:
Host-Pathogen Interactions in the Mammalian Airway
-
批准号:6727492
-
项目类别:
-
资助金额:$31.1万
-
财政年份:2003
-
负责人:GILL DIAMOND
-
依托单位:
Host-Pathogen Interactions in the Mammalian Airway
-
批准号:7048504
-
项目类别:
-
资助金额:$30.37万
-
财政年份:2003
-
负责人:GILL DIAMOND
-
依托单位:
Host-Pathogen Interactions in the Mammalian Airway
-
批准号:6609467
-
项目类别:
-
资助金额:$31.1万
-
财政年份:2003
-
负责人:GILL DIAMOND
-
依托单位:
Host-Pathogen Interactions in the Mammalian Airway
-
批准号:6871282
-
项目类别:
-
资助金额:$31.1万
-
财政年份:2003
-
负责人:GILL DIAMOND
-
依托单位:
国内基金
海外基金
登录
查看更多内容
声致离子电流促进小胶质细胞M2极化阻断再生神经瘢痕退变免疫机制
-
批准号:82371973
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:孙迪
-
依托单位:
转运蛋白RCP调控巨噬细胞脂肪酸氧化参与系统性红斑狼疮发病的机制研究
-
批准号:82371798
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:叶俊娜
-
依托单位:
基于FCER1G基因介导免疫反应探讨迟发性聋与认知障碍相关性的机制研究
-
批准号:82371141
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:陈颖
-
依托单位:
CD27-CD28-CD8+T细胞调控儿童肝脏移植免疫耐受形成的作用和机制
-
批准号:82371791
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:刘永波
-
依托单位:
T细胞受体NRP1作为新型免疫检查点在去势抵抗性前列腺癌中的作用机制研究
-
批准号:32100631
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:刘飞
-
依托单位:
抑制FGF19/FGFR4信号通路促进肺鳞癌细胞焦亡及免疫增效的机制研究
-
批准号:32100565
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:李凡
-
依托单位:
自噬基因Epg5在诺如病毒感染过程中的作用
-
批准号:32070745
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2020
-
负责人:路群
-
依托单位:
C9ORF72-SMCR8复合物在小胶质细胞中的功能及其介导的炎症反应
-
批准号:32070743
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2020
-
负责人:杨玫
-
依托单位:
间充质干细胞通过CD73/CD39/腺苷-PI3K/Akt-Nrf2信号轴调节CD4+IL-10+IFN-γ+T细胞分化减弱GVHD机制研究
-
批准号:32070781
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2020
-
负责人:栾希英
-
依托单位:
MET通过MTOR介导的自噬调节肝癌免疫原性和治疗抗性的作用及机制研究
-
批准号:31970696
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2019
-
负责人:黄星
-
依托单位: